Innovent’s IBI343 Shows Promise in Treating Gastric Cancer, Published in Nature Medicine

Nature Medicine’s Results are Out

Announcement

Innovent Biologics, Inc., a biopharmaceutical company that manufactures, commercializes, and develops medicines for the treatment of oncology, metabolic, ophthalmology, autoimmune, cardiovascular, and other severe diseases, confirmed that the results for ‘nature medicine have been published in the phase 1 clinical study of IBI343. It is an advanced anti-CLDN18.2 ADC for the treatment of gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.

The publication of the results of a global international academic journal signifies the powerful recognition of the potential of the therapy’s clinical value and is also one of the milestones for China that aids advancement to novel anti-tumor medications. According to the study findings, a regional phase 3 clinical trial (G-HOPE-001, NCT06238843) was introduced in 2024 to analyze IBI343’s effectiveness and safety to consider it as a treatment option for advanced G/GEJ AC patients.

Medication, Causes and Reports

Gastric cancer is a known malignant tumor globally. The GLOBOCAN 2022 statistics data have declared this tumor as the fifth most common malignant tumor and also the fifth most common cause of cancer-based deaths. Around 970,000 new cases and 660,000 deaths were registered annually. China registered 359,000 new cases and 260,000 deaths from gastric cancer, which overall calculates to 37.0% and 39.4% globally, highlighting the absence of medical availability.

CLDN 18.2 is a protein that is described classically in epithelial cells on the gastric mucosa in normal physiological conditions. The past studies discovered claudin19.2’s potential to be responsive in various types of cancer. The recently published study is a worldwide phase 1 clinical trial (clinicaltrial.gov identifier: NCT05458219) that was introduced to assess the tolerability, preliminary efficacy, and safety of IBI343 in advanced solid tumor patients. In the time period of October 26, 2022, and June 30, 2024 total of 116 subjects, including advanced G/GEJ adenocarcinoma were participated in receiving IBI343 monotherapy, of which 108 were under expansion and 8 in escalation.

Survival Strategy and Response of IBI343

The study demonstrates the timeframe, median follow-ups, and the quantitative and qualitative procedures that made the clinical trial successful. The scientific study and evaluation, including the escalation and overall consideration of the study, have created strong data that exemplifies and justifies the medication (drug). The merged pharmacokinetics (PK, safety, visible response, and efficacy of data are highly in support of 6 mg/kg Q3W as the considered phase 2 dose (RP2D) of IBI343. The precise data has shown that the results are a better option as a medication.